2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. LDLR

LDLR

Low-density lipoprotein receptor

The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P2341
    Angiopep-2 hydrochloride
    		99.74%
    Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.
    Angiopep-2 hydrochloride
  • HY-NP013
    Oxidized low density lipoprotein (mouse)
    		≥98.0%
    Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration.
    Oxidized low density lipoprotein (mouse)
  • HY-P4073
    ANG1005
    		98.83%
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
    ANG1005
  • HY-101529
    Imanixil
    		99.03%
    Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development.
    Imanixil
  • HY-125544
    LY 295427
    		Modulator ≥98.0%
    LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research.
    LY 295427
  • HY-167873
    Habenariol
    		Inhibitor
    Habenariol is a substantial phenolic antioxidant activity that can be isolated from the freshwater orchid, Habenaria repens.
    Habenariol
  • HY-P10697
    VH4127
    		Modulator
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR.
    VH4127
  • HY-P10698
    VH-N412
    VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
    VH-N412
  • HY-120651
    LDL-IN-2
    		Inhibitor ≥99.0%
    LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation.
    LDL-IN-2
  • HY-P99822
    Recaticimab
    		99.71%
    Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia.
    Recaticimab
  • HY-P99793
    Orticumab
    		Inhibitor ≥99.0%
    Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
    Orticumab
  • HY-100144
    Pirozadil
    		98.31%
    Pirozadil is a hypolipidemic agent.
    Pirozadil
  • HY-P990143
    Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6)
    		Inhibitor
    Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is a mouse-derived IgG1, λ type antibody inhibitor, targeting to mouse/rat/Bovine VLDL-R.
    Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6)
  • HY-U00054
    LDL-IN-3
    		Inhibitor
    LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.
    LDL-IN-3
  • HY-P10502
    L57
    		Ligand
    L57 exhibits high affinity to the low-density lipoprotein receptor-related protein 1 (LRP1) with Ki of 45 nM. L57 exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 can be utilized as the carrier for CNS drug delivery.
    L57
  • HY-147279
    Milpocitide
    Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1).
    Milpocitide
  • HY-161941
    MeIm
    MeIm (compound 7) is a high-affinity PCSK9 targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC50=6.04 μM) by inhibiting the binding of PCSK9 to LDLR (IC50=11.2 μM). MeIm can be used in the study of cardiovascular diseases.
    MeIm
  • HY-126551
    Butenoyl-PAF
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
  • HY-159595
    PCSK9-IN-29
    		Inducer
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity.
    PCSK9-IN-29
  • HY-123260
    S12340
    		Inhibitor
    S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress.
    S12340
Cat. No. Product Name / Synonyms Application Reactivity